Checkpoint inhibitors are antibody-based cancer therapies that unlock the immune system’s natural ability to fight cancer. These treatments work by blocking special proteins called immune checkpoints, ...
Immune checkpoints are regulators of the immune system. The interaction between PD-L1 (red molecule) on the surface of a cancer cell (red) and the immune checkpoint PD-1 (blue molecule) on a T-cell ...
ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical synergy with Topoisomerase 1 (Topo 1) inhibitors, commonly used payloads in antibody-drug conjugates ...
Please provide your email address to receive an email when new articles are posted on . The mechanisms governing immune-related adverse events resulting from checkpoint inhibition therapy for cancer ...
Immune checkpoint inhibitors are well known as a form of cancer treatment. Researchers at UZH have now identified a new, important function of these inhibitors: promotion of tissue healing. This ...
Immune checkpoint inhibitors are a type of cancer treatment that helps the immune system attack cancer cells more effectively. One of the key proteins involved in this process is Lymphocyte Activation ...
VANCOUVER, Washington, May 13, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for ...
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today ...
Immune checkpoint inhibitors (ICI) are a core mainstay of cancer care. In routine practice, the Time of Day of Administration (ToDA) of ICIs invariably is not stipulated in the clinical notes. Thus, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results